Company Overview and News
Market players will be looking for signs of a sustained recovery in the local stock market after a turbulent week in global markets, even as the 11th Malaysia Plan (11MP) and China’s third-quarter gross domestic product data — due to be released this Friday — will be in focus.
SLLXF 0048 4219 5109 0032
KUALA LUMPUR, Sept 25 — Berjaya Land Bhd’s (BLand) net profit jumped 43.8 per cent year-on-year to RM16.58 million for the first quarter ended July 31, 2018, on higher profit contribution from Sports Toto Malaysia Sdn Bhd (STMSB) as well as lower finance cost.
1562 4219 BSMAF 1818
KUALA LUMPUR (Aug 1): Berjaya Sports Toto Bhd (BToto) has appointed Tan Sri Tan Kok Ping as non-independent and non-executive chairman of the group effective immediately, replacing Cheah Tek Kuang who has resigned.
1562 4219 BSMAF 7087 1818
KUALA LUMPUR (June 27): Based on corporate announcements and news flow today, stocks in focus for Thursday (June 28) may include the following: Country Heights Holdings Bhd, TA Global Bhd, Berjaya Land Bhd, MGB Bhd, EA Technique (M) Bhd, Gamuda Bhd, Yinson Holdings Bhd, Borneo Oil Bhd and Comfort Gloves Bhd.
5789 7293 5738 4219 2127 7036 5158
KUALA LUMPUR (June 27): Berjaya Land Bhd, which is controlled by tycoon Tan Sri Vincent Tan, wrapped up its financial year ended April 30, 2018 (FY18) with another quarter of net loss, due mainly to unfavourable foreign exchange rates, and lower profit contribution from its number forecast operator business.
PETALING JAYA: Berjaya Land Bhd (BLand) is selling its entire stake in Vietnam-based Berjaya Vietnam Financial Centre Ltd (BVFC Ltd) for RM154.86mil to the country’s biggest property developer.
4219 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...